VEGFA and Miyoshi myopathy: Future studies should address strategies for multi-target inhibitors (e.g., dual inhibitors, bispecific antibodies) as well as the combination of anti-VEGF/VEGFR inhibitors with currently used anti-MM drugs such as PIs, IMIDs, and monoclonal antibodies.